Avoiding False Positives Key Priority in Cardiac Safe... (ceutical and biotechnology professionals...)

Avoiding False Positives Key Priority in Cardiac Safety Studies

Date:5/4/2009

ceutical and biotechnology professionals responded to the survey which was conducted between February 25th and April 21st of 2009.

About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/false_positives/cardiac_safety/prweb2365904.htm.

0

GOOD

Page: 1 2
Related biology technology :

1. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
2. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
3. Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. FDA Issues Draft Guidance on Priority Review Vouchers
6. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
7. Genta Restructures Operations to Focus on Priority Initiatives
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
11. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company

Post Your Comments:

Avoiding False Positives Key Priority in Cardiac Safe...(ceutical and biotechnology professionals...)